Solid Tumors

Oncology
154
Pipeline Programs
30
Companies
50
Clinical Trials
11 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
123
19
11
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1862%
Monoclonal Antibody
931%
RNA Therapeutic
13%
Vaccine
13%
+ 130 programs with unclassified modality

Competitive Landscape

64 companies ranked by most advanced pipeline stage

Novartis
5 programs
3
1
1
dovitinibPhase 2/3Small Molecule1 trial
BGT226Phase 1/21 trial
GWN323Phase 11 trial
Patupilone and OmeprazolePhase 1Small Molecule1 trial
gimatecanPhase 11 trial
Active Trials
NCT02740270Completed92Est. Mar 2020
NCT00420615Completed34
NCT00420485Completed120Est. Nov 2010
+2 more trials
M&
13 programs
12
1
NavarixinPhase 21 trial
ARQ 761Phase 11 trial
M3541Phase 11 trial
MK-8242Phase 12 trials
MK2206 every other dayPhase 11 trial
+8 more programs
Active Trials
NCT01502800Completed91Est. Mar 2019
NCT03225105TerminatedEst. Apr 2020
NCT01463696Terminated48Est. Oct 2015
+11 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
12 programs
10
1
AfatinibPhase 2Small Molecule1 trial
BI 1703880Phase 11 trial
BI 1821736Phase 11 trial
BI 1831169Phase 11 trial
BI 1831169Phase 11 trial
+7 more programs
Active Trials
NCT05107193No Longer Available
NCT05471856Recruiting66Est. Sep 2028
NCT05839600Terminated10Est. Apr 2025
+9 more trials
E
7 programs
6
1
E7080Phase 21 trial
E7016 + TMZPhase 11 trial
E7050Phase 11 trial
E7130Phase 11 trial
Eribulin-LFPhase 11 trial
+2 more programs
Active Trials
NCT01127178Terminated12Est. Feb 2011
NCT00921869Completed16Est. Jun 2011
NCT03444701Completed62Est. Dec 2024
+4 more trials
Roche
6 programs
3
2
1
Screening platformPhase 21 trial
CobimetinibPhase 1/2Small Molecule1 trial
EntrectinibPhase 1/2Small Molecule1 trial
AtezolizumabPhase 1Monoclonal Antibody1 trial
Eciskafusp AlfaPhase 12 trials
+1 more programs
Active Trials
NCT02350673Completed70Est. Dec 2019
NCT06816017Withdrawn0Est. Oct 2030
NCT04303858Completed189Est. Oct 2025
+4 more trials
Amgen
5 programs
3
1
1
AMG 706Phase 21 trial
BemarituzumabPhase 1/2Monoclonal Antibody3 trials
MT110Phase 11 trial
OprozomibPhase 15 trials
PanitumumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT00635596Completed65Est. Jan 2015
NCT02244112Terminated43Est. Jul 2019
NCT01999335Terminated33Est. Apr 2019
+8 more trials
Bayer
4 programs
3
1
BAY94-9343Phase 23 trials
BAY1436032Phase 11 trial
OMP-54F28Phase 11 trial
SorafenibPhase 1Small Molecule1 trial
Active Trials
NCT02746081Completed81Est. Dec 2024
NCT01608867Completed26Est. Jun 2017
NCT00572078Completed27Est. Sep 2014
+3 more trials
Bristol Myers Squibb
1
1
1
ISA 101Phase 21 trial
NivolumabPhase 1/2Monoclonal Antibody1 trial
Iso-FludelonePhase 11 trial
Active Trials
NCT01379287Completed29Est. Jan 2023
NCT02593786Completed58Est. Sep 2021
NCT02426892Completed33Est. Nov 2021
Regeneron
RegeneronTARRYTOWN, NY
3 programs
2
1
SAR444881Phase 2
nesvacumabPhase 1Monoclonal Antibody
nesvacumabPhase 1Monoclonal Antibody
Apollomics
1 program
1
APL-101 Oral CapsulesPhase 21 trial
Active Trials
NCT03175224RecruitingEst. Nov 2026
Teva
TevaIsrael - Petach Tikva
1 program
1
BalugrastimPhase 21 trial
Active Trials
NCT01940601Withdrawn0Est. Dec 2015
Rain Oncology
1 program
1
RAIN-32Phase 21 trial
Active Trials
NCT05012397TerminatedEst. Oct 2023
BioInvent International
2 programs
1
1
BI-1910Phase 1/21 trial
TB-403Phase 11 trial
Active Trials
NCT00702494Completed21Est. Sep 2009
NCT06205706Active Not Recruiting35Est. Nov 2028
Zai Lab
2 programs
1
1
ZL-1310Phase 1/21 trial
ZL-6201Phase 11 trial
Active Trials
NCT07374848Recruiting180Est. Sep 2029
NCT06885281Recruiting112Est. Dec 2027
Jacobio Pharmaceuticals
2
JAB-2485Phase 1/21 trial
JAB-30355Phase 1/21 trial
Active Trials
NCT05490472RecruitingEst. Aug 2027
NCT06386146RecruitingEst. Jul 2027
ABL Bio
1 program
1
ABL103Phase 1/2
Taiho Oncology
Taiho OncologyNJ - Princeton
1 program
1
ASTX660Phase 1/21 trial
Active Trials
NCT02503423Active Not RecruitingEst. Dec 2025
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
Cyclophosphamide and JX-594 dose escalationPhase 1/2
FUJIFILM Pharma
1
FF-10502-01Phase 1/21 trial
Active Trials
NCT02661542CompletedEst. Nov 2020
InnoCare
InnoCareChina - Beijing
1 program
1
ICP-723Phase 1/21 trial
Active Trials
NCT04685226Recruiting310Est. Feb 2028
I
1 program
1
IDX-1197Phase 1/21 trial
Active Trials
NCT04174716CompletedEst. Jun 2024
Philogen
1 program
1
L19TNFaPhase 1/21 trial
Active Trials
NCT01253837Completed34Est. Sep 2011
Seqker Biosciences
Seqker BiosciencesThailand - Bangkok
1 program
1
Personalized Neoantigen Peptide VaccinePhase 1/2Vaccine1 trial
Active Trials
NCT07002203RecruitingEst. Aug 2027
Corcept Therapeutics
1
Relacorilant with nab-paclitaxelPhase 1/21 trial
Active Trials
NCT02762981Completed85Est. Sep 2020
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
Vorinostat and EtoposidePhase 1/2
DS
Daiichi SankyoChina - Shanghai
12 programs
12
AC480IVPhase 11 trial
CS-7017 and BexarotenePhase 11 trial
Compound AC220Phase 12 trials
DS-2243aPhase 11 trial
DS-2248Phase 11 trial
+7 more programs
Active Trials
NCT01245543Withdrawn0Est. Jun 2013
NCT01504490Terminated9Est. Dec 2016
NCT01049893Completed45Est. Nov 2011
+11 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
9 programs
9
AZD1152Phase 11 trial
AZD2281Phase 11 trial
AZD2281Phase 11 trial
AZD6094 200 mgPhase 11 trial
AZD8055Phase 11 trial
+4 more programs
Active Trials
NCT00497731Terminated70Est. Apr 2009
NCT00819221Terminated44Est. Dec 2021
NCT00777582Active Not Recruiting197Est. Mar 2026
+10 more trials
Pfizer
PfizerNEW YORK, NY
7 programs
6
ErlotinibPhase 1Small Molecule5 trials
ONT-10Phase 11 trial
ONT-10Phase 11 trial
PF-03814735Phase 11 trial
PF-04449913Phase 11 trial
+2 more programs
Active Trials
NCT01574235Completed2,114Est. Feb 2014
NCT00998036Completed9Est. Oct 2012
NCT00770263Completed46Est. Sep 2014
+8 more trials
Mereo BioPharma
Mereo BioPharmaUK - London
5 programs
5
DocetaxelPhase 11 trial
OMP-18R5Phase 11 trial
OMP-21M18Phase 11 trial
OMP-54F28Phase 1
OMP-59R5Phase 11 trial
Active Trials
NCT01957007CompletedEst. Jun 2017
NCT01345201CompletedEst. May 2014
NCT00744562CompletedEst. Jan 2012
+1 more trials
Takeda
TakedaTOKYO, Japan
4 programs
4
MLN4924Phase 11 trial
TAK-102Phase 11 trial
TAK-103Phase 11 trial
[14C] SubasumstatPhase 1Small Molecule1 trial
Active Trials
NCT01862328Completed64Est. May 2018
NCT04405778Terminated12Est. May 2025
NCT05164666Terminated2Est. Feb 2025
+1 more trials

+34 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
PfizerErlotinib
Novartisdovitinib
AmgenBemarituzumab
RocheScreening platform
Rain OncologyRAIN-32
BayerBAY94-9343
EisaiE7080
Merck & Co.Navarixin
ApollomicsAPL-101 Oral Capsules
AstraZenecaSavolitinib
Bristol Myers SquibbISA 101
Boehringer IngelheimAfatinib
TevaBalugrastim
Daiichi SankyoCompound AC220
PfizerErlotinib

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 4,254 patients across 50 trials

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Start: May 2008Est. completion: Apr 2012583 patients
Phase 3Terminated

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

Start: May 2014Est. completion: Nov 201612 patients
Phase 2/3Completed
NCT06967987AmgenBemarituzumab

Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b

Start: Jan 2026Est. completion: Jan 20260
Phase 2Withdrawn
NCT05419375RocheScreening platform

Screening Study for Participants With Malignant Tumors

Start: Jul 2022Est. completion: Sep 2025470 patients
Phase 2Completed

Milademetan in Advanced/Metastatic Solid Tumors

Start: Nov 2021Est. completion: Oct 2023
Phase 2Terminated

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Start: Jun 2019Est. completion: May 20229 patients
Phase 2Terminated

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Start: Aug 2018Est. completion: Dec 202340 patients
Phase 2Completed

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Start: Apr 2018Est. completion: May 2021107 patients
Phase 2Completed
NCT03175224ApollomicsAPL-101 Oral Capsules

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Start: Sep 2017Est. completion: Nov 2026
Phase 2Recruiting

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

Start: May 2016Est. completion: Jul 202469 patients
Phase 2Completed

Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors

Start: Dec 2015Est. completion: Nov 202133 patients
Phase 2Completed

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Start: Aug 2015Est. completion: May 202312 patients
Phase 2Completed
NCT01940601TevaBalugrastim

Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors

Start: Sep 2014Est. completion: Dec 20150
Phase 2Withdrawn

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Start: Nov 2009Est. completion: Dec 2014333 patients
Phase 2Completed

Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III

Start: Feb 2008Est. completion: Mar 2015212 patients
Phase 2Unknown

An Open Label Treatment Extension Study of AMG 706

Start: Dec 2005Est. completion: Jul 201294 patients
Phase 2Terminated

A Study of ZL-1310 in Participants With Selected Solid Tumors

Start: May 2025Est. completion: Dec 2027112 patients
Phase 1/2Recruiting

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Start: Jul 2024Est. completion: Jul 2027
Phase 1/2Recruiting
NCT07002203Seqker BiosciencesPersonalized Neoantigen Peptide Vaccine

Personalized Neoantigen Peptide Vaccines for Solid Tumors

Start: Mar 2024Est. completion: Aug 2027
Phase 1/2Recruiting

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Start: Dec 2023Est. completion: Nov 202835 patients
Phase 1/2Active Not Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Start: Dec 2022Est. completion: Aug 2027
Phase 1/2Recruiting
NCT05325866AmgenBemarituzumab

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Start: Sep 2022Est. completion: Jan 2026260 patients
Phase 1/2Completed
NCT05322577AmgenBemarituzumab

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Start: May 2022Est. completion: Aug 202672 patients
Phase 1/2Active Not Recruiting

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Start: Sep 2020Est. completion: Feb 2028310 patients
Phase 1/2Recruiting

Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS)

Start: Nov 2019Est. completion: Jun 2024
Phase 1/2Completed
NCT02762981Corcept TherapeuticsRelacorilant with nab-paclitaxel

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Start: May 2016Est. completion: Sep 202085 patients
Phase 1/2Completed
NCT02639546RocheCobimetinib

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

Start: May 2016Est. completion: Jul 202156 patients
Phase 1/2Completed
NCT02650401RocheEntrectinib

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Start: May 2016Est. completion: Jun 202669 patients
Phase 1/2Active Not Recruiting

A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors

Start: Jan 2016Est. completion: Sep 202158 patients
Phase 1/2Completed

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

Start: Jan 2016Est. completion: Nov 2020
Phase 1/2Completed

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Start: Jul 2015Est. completion: Dec 2025
Phase 1/2Active Not Recruiting

A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

Start: Jan 2014Est. completion: Sep 20159 patients
Phase 1/2Completed

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Start: Oct 2013Est. completion: Sep 201922 patients
Phase 1/2Terminated

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Start: Jul 2013Est. completion: Jun 201965 patients
Phase 1/2Terminated

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Start: Dec 200757 patients
Phase 1/2Completed

L19TNFα in Patients With Advanced Solid Tumors

Start: Sep 2007Est. completion: Sep 201134 patients
Phase 1/2Completed

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Start: Feb 2005Est. completion: Aug 2011282 patients
Phase 1/2Completed

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Start: Mar 2026Est. completion: May 202946 patients
Phase 1Not Yet Recruiting

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Start: Mar 2026Est. completion: Feb 203260 patients
Phase 1Not Yet Recruiting

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Start: Mar 2026Est. completion: Sep 2029180 patients
Phase 1Recruiting

First in Human Study of QLS5316 in Solid Tumors

Start: Jan 2026Est. completion: Dec 2027
Phase 1Not Yet Recruiting

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Start: Nov 2025Est. completion: Nov 202763 patients
Phase 1Recruiting

A Study of DS3610a in Participants With Advanced Solid Tumor

Start: Oct 2025Est. completion: Feb 203170 patients
Phase 1Recruiting
NCT06816017RocheEciskafusp Alfa

A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Start: Jun 2025Est. completion: Oct 20300
Phase 1Withdrawn

Study of AUBE00 in Patients With Solid Tumors

Start: Jun 2025Est. completion: Dec 2029130 patients
Phase 1Recruiting

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

Start: Nov 2024Est. completion: Nov 2028150 patients
Phase 1Recruiting

A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers

Start: Apr 2024Est. completion: Jun 20247 patients
Phase 1Completed
NCT05976334Takeda[14C] Subasumstat

An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Start: Nov 2023Est. completion: Jul 20243 patients
Phase 1Terminated

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Start: Oct 2023Est. completion: Nov 202645 patients
Phase 1Active Not Recruiting

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Start: Jul 2023Est. completion: May 2024
Phase 1Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

11 actively recruiting trials targeting 4,254 patients
30 companies competing in this space